Evidence map›Paper›PMID 39957692›Full record

ReviewCurrent drug safety2026

Advancements in Colon Cancer Therapy: A Review on Docetaxel and the Role of Nanotechnology in Enhancing Efficacy.

Komal, Dinesh Kumar, Sharib Raza Khan, Prabhjot Kaur, Kankan Majumdar, Nabaparna Chakraborty, Amandeep Singh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

KomalFaculty of Pharmaceutical Sciences , PCTE Group of Institutes, Ferozepur Road, Near Baddowal Cantt, Jhandey, Ludhiana, India.
Dinesh KumarDepartment of Quality Assurance, ISF College of Pharmacy, Moga, Punjab, 142001, India.
Sharib Raza KhanDivision of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India.
Prabhjot KaurDepartment of Food and Nutrition, Punjab Agricultural University, Ludhiana, Punjab , 141004, India.
Kankan MajumdarDepartment of Molecular Biology & Genetic Engineering, School of Bio-engineering & Biosciences, Lovely Professional University, Punjab, India.
Nabaparna ChakrabortyCentral Instrumentation Facility, Research and Development Cell, Lovely Professional University, Phagwara, Punjab, 144411, India.
Amandeep SinghDepartment of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, 142001, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Docetaxel exhibits high protein binding and P450-mediated metabolism, which influences its pharmacokinetics. As a taxane-family chemotherapeutic agent, it stabilizes microtubules and disrupts cell division. Combining docetaxel with agents like 5-fluorouracil and oxaliplatin enhances treatment outcomes for colon cancer. Emerging drug delivery systems, including nanoparticles and micelles, aim to improve efficacy while reducing toxicity. However, its safety during pregnancy remains uncertain, and ongoing clinical trials continue to evaluate its therapeutic potential.

Indexed as

Antineoplastic AgentsColonic NeoplasmsNanotechnologyTaxoidsAnimalsDocetaxelDrug Delivery SystemsHumansMicellesNanoparticlesAntineoplastic AgentsDocetaxelMicellesTaxoidschemotherapyclinical trialsColon cancerdocetaxeldrug delivery systemsmicellesmicrotubule stabilizationnanoparticlespharmacokinetics

Identifiers

PMID39957692

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.